The Israeli diagnostics company Improdia has signed a cooperation agreement with Tel Aviv Sourasky Medical Center (Ichilov) to perform a large-scale clinical trial on diabetes patients aimed at preventing lethal complications based on their immune status.
Today there is no test that distinguishes between acute inflammation, which helps the body overcome the disease, and chronic inflammation that causes a low immune level. In a clinical trial performed on diabetics, Improdia showed that a decrease in the immune status in patients, as expressed by Improdias’ unique biological markers, causes complications such as a cardiac incidents and even mortality.
Dr. Roy Eldor, head of the Diabetes Unit at the Institute of Endocrinology, Metabolism and Hypertension at the Ichilov Hospital, and a member of the Scientific Advisory Committee of Improdia, performed a clinical trial testing the involvement of the unique biological markers that Improdia developed, in type 2 diabetes patients.1 The study found that a high percentage of the subjects with a low immune status, based on Improdias’ marker, developed a cardiac event within 20 months. Due to the success of the research, the company has prepared a protocol for a large scale clinical trial that will include above 5000 volunteers. The trial will examine the possibility of using Improdia`s technology to monitor the level of the immune system through the unique biological markers for chronic inflammation, as a screening test for diabetes patients that predicts complications and enables preventive measures to be taken.
1 CD247, a Novel T Cell-Derived Diagnostic and Prognostic Biomarker for Detecting Disease Progression and Severity in Patients with Type 2 Diabetes Mellitus; Eldor R., Klieger Y., Sade-Feldman M., Vaknin I., Varfolomeev I., Fuchs C. and Baniyash M.; Diabetes Care, Jan. 2015; 38(1): 113-118